Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. - Ortiz-Maldonado V; Rives S; Español-Rego M; Alonso-Saladrigues A; Montoro M; Magnano L; Giné E; Pascal M; Díaz-Beyá M; Castella M; Català A; Faura A; et al. (Journal for immunotherapy of cancer, 2021)